You are here

Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-10-C-0005
Agency Tracking Number: A2-4234
Amount: $629,510.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: A09-107
Solicitation Number: 2009.2
Timeline
Solicitation Year: 2009
Award Year: 2011
Award Start Date (Proposal Award Date): 2011-08-01
Award End Date (Contract End Date): N/A
Small Business Information
P.O. Box 100
Ithaca, NY -
United States
DUNS: 022552900
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Mehran Pazirandeh
 Staff Scientist
 (607) 272-0002
 mehranp@agavebio.com
Business Contact
 Noe Salazar
Title: President
Phone: (512) 373-8601
Email: nsalazar@agavebio.com
Research Institution
 Stub
Abstract

Recent studies have suggested the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems is creating a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.In the Phase I, Agave BioSystems successfully demonstrated proof-of concept for this novel platform.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government